AKT1 and neoplasm: Indeed, combination therapy with PI3K/AKT and MEK inhibitors could be a promising strategy in several tumor types, including mCRPC (Kinkade et al., 2008; Ewald et al., 2014; Park et al., 2015; Toren et al., 2016; Marques et al., 2020).